Annexin Financial Statements From 2010 to 2024
| ANNX Stock | SEK 0.54 0.06 12.50% |
Check Annexin Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Annexin Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Annexin financial statements analysis is a perfect complement when working with Annexin Pharmaceuticals Valuation or Volatility modules.
Annexin |
Annexin Pharmaceuticals AB Company Shares Owned By Insiders Analysis
Annexin Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Annexin Pharmaceuticals Shares Owned By Insiders | 45.17 % |
Most of Annexin Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Annexin Pharmaceuticals AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 45.166% of Annexin Pharmaceuticals AB are shares owned by insiders. This is 197.54% higher than that of the Healthcare sector and 218.52% higher than that of the Biotechnology industry. The shares owned by insiders for all Sweden stocks is notably lower than that of the firm.
Annexin Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Annexin Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Annexin Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Annexin Pharmaceuticals competition to find correlations between indicators driving Annexin Pharmaceuticals's intrinsic value. More Info.Annexin Pharmaceuticals AB is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Annexin Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Annexin Pharmaceuticals Financial Statements
Annexin Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Annexin Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Annexin Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Annexin Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Annexin Pharmaceuticals AB , a biotechnology company, engages in developing drug candidates for the treatment of various cardiovascular diseases. The company was founded in 2014 and is based in Stockholm, Sweden. Annexin Pharmaceuticals is traded on Stockholm Stock Exchange in Sweden.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Annexin Stock Analysis
When running Annexin Pharmaceuticals' price analysis, check to measure Annexin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Annexin Pharmaceuticals is operating at the current time. Most of Annexin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Annexin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Annexin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Annexin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.